Option Therapeutics

BioVie liver disease carve-out Option Therapeutics files and sets terms for a $25 million IPO IPO Overview Option Therapeutics, a Phase 2 liver disease biotech spun out of BioVie, filed on Monday with the SEC to raise up to $25... Read more